Inhibition of Tumor Growth and Sensitization to Sunitinib by RNA Interference Targeting Programmed Death-ligand 1 in Mouse Renal Cell Carcinoma RenCa Model
- PMID: 31519573
- DOI: 10.21873/anticanres.13656
Inhibition of Tumor Growth and Sensitization to Sunitinib by RNA Interference Targeting Programmed Death-ligand 1 in Mouse Renal Cell Carcinoma RenCa Model
Abstract
Background/aim: There are several unresolved issues regarding the combined treatment with an immune checkpoint inhibitor and anti-angiogenic agent for renal cell carcinoma (RCC) patients. The purpose of this study was to address the inhibitory effects of programmed death-ligand 1 (PD-L1) expression on growth and sensitivity to sunitinib in the mouse RCC RenCa model.
Materials and methods: We established RenCa/sh-PD-L1 by transfecting RenCa cells with a plasmid carrying a short hairpin RNA targeted against PD-L1. The growth pattern of RenCa/sh-PD-L1 with or without sunitinib was compared to that of RenCa cells transfected with control plasmid alone (RenCa/Co).
Results: No significant difference in growth or sensitivity to sinitinib was noted between RenCa/sh-PD-L1 and RenCa/Co cells in vitro. The tumor volume in mice subcutaneously injected with RenCa/sh-PD-L1 was significantly smaller than that with RenCa/Co. Treatment of mice bearing each tumor with sunitinib resulted in a significant reduction of the RenCa/sh-PD-L1 tumor compared to the RenCa/Co tumor. Moreover, infiltration by CD8+ T cells of RenCa/sh-PD-L1 tumors was significantly higher than that of RenCa/Co tumors, irrespective of treatment with sunitinib.
Conclusion: Suppressed expression of PD-L1 could increase tumor-infiltrating CD8+ T cells and result in growth inhibition as well as enhanced sensitivity to sunitinib in the RenCa model.
Keywords: CD8+ T cells; PD-L1; RenCa; Renal cell carcinoma; sunitinib.
Copyright© 2019, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.
Similar articles
-
Anti-PD-L1 treatment enhances antitumor effect of everolimus in a mouse model of renal cell carcinoma.Cancer Sci. 2016 Dec;107(12):1736-1744. doi: 10.1111/cas.13099. Epub 2016 Dec 13. Cancer Sci. 2016. PMID: 27712020 Free PMC article.
-
Correlation of PD-L1 tumor expression and treatment outcomes in patients with renal cell carcinoma receiving sunitinib or pazopanib: results from COMPARZ, a randomized controlled trial.Clin Cancer Res. 2015 Mar 1;21(5):1071-7. doi: 10.1158/1078-0432.CCR-14-1993. Epub 2014 Dec 23. Clin Cancer Res. 2015. PMID: 25538263 Clinical Trial.
-
T-cell responses and combined immunotherapy against human carbonic anhydrase 9-expressing mouse renal cell carcinoma.Cancer Immunol Immunother. 2022 Feb;71(2):339-352. doi: 10.1007/s00262-021-02992-7. Epub 2021 Jun 23. Cancer Immunol Immunother. 2022. PMID: 34160685 Free PMC article.
-
Targeted literature review on use of tumor mutational burden status and programmed cell death ligand 1 expression to predict outcomes of checkpoint inhibitor treatment.Diagn Pathol. 2020 Jan 30;15(1):6. doi: 10.1186/s13000-020-0927-9. Diagn Pathol. 2020. PMID: 32000815 Free PMC article. Review.
-
Hyper-interleukin-11 novel designer molecular adjuvant targeting gp130 for whole cell cancer vaccines.Expert Opin Biol Ther. 2011 Dec;11(12):1555-67. doi: 10.1517/14712598.2011.627852. Epub 2011 Oct 14. Expert Opin Biol Ther. 2011. PMID: 21995459 Review.
Cited by
-
Experimental and computational modeling for signature and biomarker discovery of renal cell carcinoma progression.Mol Cancer. 2021 Oct 20;20(1):136. doi: 10.1186/s12943-021-01416-5. Mol Cancer. 2021. PMID: 34670568 Free PMC article.
-
Assessments of therapeutic effects according to timings for combined therapy with axitinib and immune check point inhibitor in a mouse renal cell carcinoma model.Sci Rep. 2023 Jul 13;13(1):11361. doi: 10.1038/s41598-023-37857-9. Sci Rep. 2023. PMID: 37443122 Free PMC article.
-
Interval Between Cancer Diagnosis and Radiotherapy - An Independent Prognostic Factor of Survival in Patients Irradiated for Bone Metastases from Kidney Cancer.In Vivo. 2020 Mar-Apr;34(2):767-770. doi: 10.21873/invivo.11836. In Vivo. 2020. PMID: 32111782 Free PMC article.
-
Combination of Anti-Angiogenics and Checkpoint Inhibitors for Renal Cell Carcinoma: Is the Whole Greater Than the Sum of Its Parts?Cancers (Basel). 2022 Jan 27;14(3):644. doi: 10.3390/cancers14030644. Cancers (Basel). 2022. PMID: 35158916 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
